Supported by Oxford Science Enterprises, the merger of the two University of Oxford spinout companies brings together drug discovery and clinical development capabilities, which streamlines the R&D process and ensures pipeline continuity.
IngenOx Therapeutics will focus on delivering new precision medicine drugs and vaccines to treat the most difficult cancers, often referred to as cold tumours. Its pipeline comprises early to late-stage clinical assets that work in different ways to activate the immune response against cold tumours, which are generally poorly recognised by the immune system. An exciting proprietary platform technology focusses on precision cancer vaccines that act by targeting the immune response to a novel source of cancer antigens.
The Penningtons Manches Cooper team advising Celleron Therapeutics was led by corporate partner James Went with corporate senior associate Lindsay Chadwick, and included support from corporate tax partner Kathy Hills and corporate tax associate Leonie Langley.
Nick La Thangue, CEO of IngenOx, and Professor of Cancer Biology at the University of Oxford commented:
“We are very excited by the merger which creates a company with a highly innovative pipeline, a talented and driven management team supported by a balanced group of investor shareholders. IngenOx has the critical mass to bring a range of novel cancer therapies through clinical development and onwards towards market launch. I’d like to thank James Went and the wider team at Penningtons Manches Cooper for their expertise and advice on this strategically important merger which provides the basis for success and future growth.”
James Went, corporate partner at Penningtons Manches Cooper said: “We are delighted to have worked with the team at Celleron Therapeutics on the completion of this key strategic transaction. This builds on our long term relationship with Celleron and we look forward to supporting Ingenox as they continue their important work on these difficult to treat cancers.”
The team at Penningtons Manches Cooper specialises in working with innovative life sciences companies, advising on all aspects of their legal needs.